近年来，CD40和CD40L逐渐走入科研的前沿，成为免疫系统研究的重要焦点。作为一种跨膜蛋白，CD40在抗原呈递细胞表面大放异彩，尤其在B细胞、巨噬 ...

The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

Both parties had claimed monoclonal antibodies with specificity for CD40 ligand (CD40L). The Lederman claims were directed to antibodies specific for human CD40L, whereas Noelle claimed antibodies ...

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more about ELDN stock here.

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

Further support for this concept comes from animal models of autoimmunity and transplantation, where treatments based on costimulation blockade, in particular CD40 ligand (CD40L)-specific ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. | Novartis has finally given up on iscalimab after deciding that the ...

Eledon Pharmaceuticals (ELDN) announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a key component of the ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...